TomoTherapy, Inc. (TOMO.OB), the developer and manufacturer of the Hi-Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers, recently delivered its growth initiatives during a presentation at the Citigroup Global Health Care Conference in New York, New York.

The oncology market in the United States exceeds $2.5 billion and is growing at an annual rate of nearly 14 percent, generating a significant opportunity for the company. TomoTherapy plans to continue to innovate and further globalize its market presence. The company is expected to cover 93 percent of the radiation therapy system market worldwide this year.

TomoTherapy continues to record strong order activity, doubling market growth in the first quarter of 2008. The company has a current backlog of $260 million and significant long-term growth prospects. To elevate annual revenues, TomoTherapy intends to leverage its fixed service and support infrastructures to generate a 40 percent increase in gross margins in 2009.

Let us hear your thoughts below: